Comparison of PERCIST5, imPERCIST5, and PERCIMT Criteria for Early Assessment of Pembrolizumab Response with FDG-PET/CT in Metastatic Bladder Cancer Patients

Comparison of PERCIST5, imPERCIST5, and PERCIMT Criteria for Early Assessment of Pembrolizumab Response with FDG-PET/CT in Metastatic Bladder Cancer Patients

<b>Background/Objectives:</b> Immunotherapy is an essential part of metastatic bladder cancer treatment. Our main objective was to study the prognostic value of FDG-PET/CT in early assessment of response to Pembrolizumab in metastatic bladder cancers using PERCIST5, imPERCIST5, and PERCI...

Full description

Saved in:
Bibliographic Details
Main Authors: Marc Bertaux, Caroline Luo, Camelia Radulescu, Philippe Beuzeboc, Cecile Landais, Pauline Touche, Christine Abraham, Marie Homo Seban, Eve Camps, Antoine Faucheron, Morgan Tourne, Lucie Fricot, Lea Turpin, Romain-David Seban, Sabrina Khedairia
Format: Article
Language:English
Published: MDPI AG 2025-05-01
Series:Pharmaceuticals
Subjects:
bladder cancer
immunotherapy
[18F]-fluorodeoxyglucose
positron emission tomography
Pembrolizumab
Online Access:https://www.mdpi.com/1424-8247/18/5/701
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/1424-8247/18/5/701

Similar Items